Kalos Management, Inc. Amicus Therapeutics, Inc. Transaction History

Kalos Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$12.89 - $15.89 $130,833 - $161,283	-10,150 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$7.48 - $10.75 $5,236 - $7,525	-700 Reduced 6.45%	10,150 $98,000
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $35,006 - $45,993	3,194 Added 41.72%	10,850 $135,000
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $31,063 - $43,068	-3,094 Reduced 28.78%	7,656 $104,000
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $124,700 - $177,805	10,750 New	10,750 $126,000
Q1 2018 May 14, 2018	SELL	$13.76 - $17.12 $147,920 - $184,040	-10,750 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $134,482 - $174,579	10,750	10,750 $154,000

313

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.71B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.